As part of its advocacy program in Europe, ACRO submits regulatory comments to European officials. This comment letter, submitted by ACRO to European Commission in 2023 about Multi-stakeholder open letter expressing concerns regarding the impact of IVDR implementation on patient access to clinical trials can be found below.